Interact with experts and peers.

Recent Posts

10 of 112 Shown
  • CLL Studies Presented at the 2016 Hematology Meeting Confirm Ibrutinib’s Long-term Efficacy and Suggest Benefit From Second-line Agents

    Jeffrey A. Jones MD, MPH - 1/6/2017
    Do you know how recent CLL results presented at ASH 2016 could change your practice? Read my thoughts on ibrutinib and what to do after treatment failure.
  • My Thoughts on Key Myelofibrosis and Polycythemia Vera Management Studies From the Hematology 2016 Meeting

    Brady L. Stein MD, MHS - 12/30/2016 1 comment / Last Comment: 1/11/2017
    In this commentary, I highlight study findings from the 2016 Hematology meeting that may affect management of patients with myelofibrosis or polycythemia vera.
  • A Banner Year for Myeloma at the 2016 Hematology Meeting

    Shaji Kumar MD - 12/27/2016
    Multiple practice-changing myeloma studies were presented at ASH this year. In this commentary, I discuss several key findings clinicians should be aware of.
  • Atezolizumab: A New Treatment Option for Progressive Metastatic NSCLC

    Melissa L. Johnson MD - 12/20/2016 1 comment / Last Comment: 12/21/2016
    There is now a third checkpoint inhibitor approved for metastatic NSCLC. Melissa L. Johnson, MD, discusses the latest clinical data from ESMO 2016 that led to the FDA approval of atezolizumab for advanced NSCLC that has progressed on previous platinum-based chemotherapy.
  • How Cabozantinib Is Transforming RCC Clinical Practice

    Won Kim MD - 12/19/2016
    Cabozantinib is changing the paradigm in RCC. How should it be integrated into your clinical practice?
  • My Treatment Approach for Very Elderly Patients With Multiple Comorbidities and Relapsed Myeloma

    Suzanne Lentzsch MD, PhD - 12/13/2016
    With many different treatment options available for patients with R/R MM, choosing the best one can be difficult. Here is how I choose treatment for elderly patients with R/R MM.
  • Preview of ASH 2016: Top Expert-Selected Studies

    John M. Burke MD - 12/1/2016 1 comment / Last Comment: 12/4/2016
    Look for these important studies at the coming Hematology meeting in San Diego. Be sure to also check our Web site frequently for downloadable PowerPoint slides featuring key presented data.
  • Immune Checkpoint Inhibitors: A New Hope for Patients With Merkel Cell Carcinoma

    Sandra P. D'Angelo MD - 11/30/2016 1 comment / Last Comment: 12/7/2016
    In this commentary, Sandra P. D’Angelo, MD, highlights the practice-changing use of immune checkpoint inhibitor therapy for the treatment of patients with metastatic Merkel cell carcinoma.
  • Clinical Dilemma: A Patient With a Diagnosis of Stage IV NSCLC-NOS Is Referred to You for a Second Opinion

    Leora Horn MD, MSc, FRCPC - 11/21/2016 2 comments / Last Comment: 11/28/2016
    In the age of targeted therapies and immune checkpoint inhibition, Leora Horn, MD, MSc, FRCPC, discusses the importance of avoiding diagnoses of lung cancer–not otherwise specified in the optimal treatment of patients with newly diagnosed, advanced NSCLC.
  • Should You Use IgHV Mutation Status to Select Optimal Choice of Therapy for Your Patients With CLL?

    Jeff P. Sharman MD - 11/16/2016
    How I incorporate IgHV mutations status in my current clinical practice.
10 of 112 Shown
Show 10 More